New combo aims to fight merkel cell cancer when immunotherapy fails
NCT ID NCT07472322
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 4 times
Summary
This study tests whether combining two drugs—ASTX727 (a pill) and retifanlimab (given through a vein)—can shrink tumors and control advanced Merkel cell cancer in people whose disease has worsened after standard immunotherapy. About 31 adults with stage III or IV Merkel cell cancer that cannot be removed by surgery will take the drugs for up to two years. The main goals are to check safety and see if the combination helps stop the cancer from growing or spreading.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASTX727 (decitabine/cedazuridine) and retifanlimab
- What this could lead to
- If it works, this combination could offer a new treatment option for people with advanced Merkel cell cancer whose disease has stopped responding to standard immunotherapy.
- What could go wrong
- This is an early-phase trial with only 31 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet known if it will be more effective than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Wisconsin-Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Blood markers could spot hidden skin cancer return
- Cancer-Killing virus shows promise in early trial for advanced tumors
- Immune cell therapy shows promise for tough cancers
- New database aims to crack the code on three rare skin cancers
- New scan could spot hidden tumors more accurately